封面
市场调查报告书
商品编码
1271274

单纯疱疹病毒治疗药市场:各药物类型,各给药途径,各地区-规模,占有率,展望,机会分析,2023年~2030年

Herpes Simplex Virus Treatment Market, By Drug Type, By Route of Administration, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: | 出版商: Coherent Market Insights | 英文 171 Pages | 商品交期: 2-3个工作天内

价格
简介目录

单纯疱疹病毒 (HSV) 是一种引起生殖器和口腔疱疹的病毒感染。它是一种传染性很强的病毒,会引起感染。HSV有两种类型,例如HSV-1和HSV-2。生殖器疱疹无法治癒,但是,每天使用抗病毒药物可以预防或缩短爆发时间,并减少将其传播给他人的机会。因此,全球对安全有效的单纯疱疹病毒治疗的需求不断增加。

单纯疱疹病毒感染流行率增加、临床试验数量增加、对安全有效 HSV 治疗的需求增加以及人们对单纯疱疹病毒认识的提高预计是在预测期内促进全球疱疹单纯病毒治疗市场成长的主要因素。

本报告对全球单纯疱疹病毒治疗市场进行了深入分析,并提供了预测期(2023-2030年)的市场规模(百万美元)和年复合成长率(CAGR %),以 2022年为基准年。

目录

第1章 调查的目的与前提条件

  • 调查的目的
  • 前提条件
  • 简称

第2章 市场展望

  • 报告概要
    • 市场定义和规模
  • 摘要整理
    • 市场概述:各药物类型
    • 市场概述:各给药途径
    • 市场概述:各地区
  • Coherent Opportunity Map(COM)

第3章 市场动态,法律规章,趋势分析

  • 市场动态
    • 单纯疱疹病毒感染疾病的盛行率上升
    • 对性感染疾病(STD)的社会污名化
    • 对安全有效的HSV治疗药的需求增加
  • 影响度分析
  • 主要的焦点
  • 法规情境
  • 产品销售/核准
  • PEST分析
  • PORTER的分析
  • 合併、收购情境

第4章 单纯疱疹病毒治疗药的全球市场- 冠状病毒(COVID-19)大流行造成的影响

  • 关于COVID-19流行病学
  • 供给侧和需求侧的分析
  • 经济影响

第5章 单纯疱疹病毒治疗药的全球市场,各药物类型,2017年~2030年

  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • 其他的药物

第6章 单纯疱疹病毒治疗药的全球市场(各给药途径):2017年~2030年

  • 口服剂
  • 注射剂
  • 外用药

第7章 单纯疱疹病毒治疗药的全球市场单纯疱疹病毒治疗药的全球市场,各地区,2017年~2030年

  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东、非洲地区

第8章 竞争情形

  • Fresenius SE & Co. KgaA
  • Glenmark Pharmaceuticals
  • Carlsbad Tech
  • GlaxoSmithKline PLC
  • Zydus Cadila
  • Epi Health LLC
  • Viatris Inc.
  • Apotex Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Emcure Pharmaceuticals Ltd(Avet Pharmaceuticals Inc.)

第9章 Section

  • 关于调查手法
  • 关于出版社
简介目录
Product Code: CMI5631

The herpes simplex virus (HSV) is a viral infection that causes genital and oral herpes. It is a very contagious virus that causes infections. There are two types of HSV, such as HSV-1 and HSV-2. There is no cure for genital herpes, however, daily use of antiviral medicines can prevent or shorten outbreaks, and reduce the chance of spreading it to others. Thus, there is an increasing demand for safe and effective herpes simplex virus treatment worldwide.

Market Dynamics:

Increase in prevalence of infections of the herpes simplex virus, rise in number of clinical trials, increase in demand for safe and effective HSV treatment, and increase in awareness among people about herpes simplex virus are major factors expected to augment the growth of the global herpes simplex virus treatment market over the forecast period.

For instance, in October 2021, United BioPharma, Shanghai Public Health Clinical Centre, and Department of Microbiology (Cheng Kung University) and Immunology teamed up to investigate the efficacy of UB-621, a best-in-class long-acting medicine for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and 2). Moreover, the World Health Organization (WHO) and partners support research to develop new strategies for prevention and control of HSV infections.

Key features of the study:

  • This report provides in-depth analysis of the global herpes simplex virus treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global herpes simplex virus treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Fresenius SE & Co. KgaA, Glenmark Pharmaceuticals, Carlsbad Tech, GlaxoSmithKline PLC, Zydus Cadila, Epi Health LLC, Viatris Inc., Apotex Inc., Teva Pharmaceuticals Industries Ltd., and Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global herpes simplex virus treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herpes simplex virus treatment market.

Detailed Segmentation:

  • Global Herpes Simplex Virus Treatment Market By Drug Type:
    • Acyclovir
    • Valacyclovir
    • Famciclovir
    • Other Drugs
  • Global Herpes Simplex Virus Treatment Market By Route of Administration:
    • Oral
    • Injection
    • Topical
  • Global Herpes Simplex Virus Treatment Market By Geography:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Company Profiles:
    • Fresenius SE & Co. KgaA
    • Glenmark Pharmaceuticals
    • Carlsbad Tech
    • GlaxoSmithKline PLC
    • Zydus Cadila
    • Epi Health LLC
    • Viatris Inc.
    • Apotex Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in prevalence of infections of the herpes simplex virus
    • Social stigma about sexually transmitted diseases (STDs)
    • Increase in demand for safe and effective HSV therapeutics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Herpes Simplex Virus Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Herpes Simplex Virus Treatment Market, By Drug Type, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Acyclovir
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Valacyclovir
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Famciclovir
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Other Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Herpes Simplex Virus Treatment Market, By Route of Administration, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Herpes Simplex Virus Treatment Market, By Geography, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)

8. Competitive Landscape

  • Fresenius SE & Co. KgaA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Glenmark Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Carlsbad Tech
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Zydus Cadila
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Epi Health LLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Viatris Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Apotex Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceuticals Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us